Zentalis Pharmaceuticals Appoints Jim Bucher as Chief Legal Officer
PUBLIC · ZNTLAug 26, 2025
Position
Corporate Secretary
Company
Zentalis Pharmaceuticals
Jim Bucher
San DiegoBiotechnologyHealthcareMedicalTherapeuticsPharmaceuticalresearch
Description
Zentalis Pharmaceuticals, Inc. has announced the appointment of Jim Bucher as Chief Legal Officer and Corporate Secretary, effective September 18, 2025. Jim brings over 30 years of legal experience in the life sciences sector and will play a vital role in advancing the company’s clinical development efforts.
Company Information
Company
Zentalis Pharmaceuticals
Location
10275 Science Center Dr
San Diego, California, United States
About
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC.
Fundz sees it the moment Zentalis Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoBiotechnologyHealthcareMedicalTherapeuticsPharmaceuticalresearch